Please use this identifier to cite or link to this item:
|Title:||Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies|
|Citation:||EUROPEAN JOURNAL OF CANCER, 2006, 42 (14), pp. 2318-2325|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.